Rational surveillance programs for early stage breast cancer patients after primary treatment

Breast Disease

Volumn 21, Issue , 2004, Pages 47-54

  Mollick, Joseph A ^a   Carlson, Robert W ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE; GAMMA GLUTAMYLTRANSFERASE; MUCIN 1; TISSUE POLYPEPTIDE ANTIGEN;

AGED; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE COURSE; EARLY DIAGNOSIS; ECHOGRAPHY; EMOTIONAL STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAMMOGRAPHY; MEDICAL ASSESSMENT; METASTASIS POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SELECTION; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT OUTCOME; WELLBEING;

EID: 12444291004     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2004-21107     Document Type: Article

References (38)

1. A. Zwaveling, G.H. Albers, W. Felthuis and J. Hermans, An evaluation of routine follow-up for detection of breast cancer recurrences, J Surg Oncol 34 (1987), 194-197.
2. T. Broyn and J. Froyen, Evaluation of routine follow-up after surgery for breast carcinoma, Acta Chir Scand 148 (1982), 401-404.
3. D.P. Winchester, S.F. Sener, J.D. Khandekar, M.A. Oviedo, M.P. Cunningham, J.A. Caprini et al., Symptomatology as an indicator of recurrent or metastatic breast cancer, Cancer 43 (1979), 956-960.
4. K.J. Pandya, E.T. McFadden, L.A. Kalish, D.C. Tormey, S.G.t. Taylor and G. Falkson, A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report, Cancer 55 (1985), 202-205.
5. T. Saphner, D.C. Tormey and R. Gray, Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol 14 (1996), 2738-2746.
6. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators, JAMA 271 (1994), 1587-1592.
7. M. Rosselli Del Turco, D. Palli, A. Cariddi, S. Ciatto, P. Pacini and V. Distante, Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up, JAMA 271 (1994), 1593-1597.
8. D. Palli, A. Russo, C. Saieva, S. Ciatto, M. Rosselli Del Turco, V. Distante et al., Intensive vs clinical follow-up aftertreatment of primary breast cancer: 10-year update ofa randomized trial. National Research Council Project on Breast Cancer Follow-up, JAMA 281 (1999), 1586.
9. R. Tornin and W.L. Donegan, Screening for recurrent breast cancer its effectiveness and prognostic value, J Clin Oncol 5 (1987), 62-67.
10. H.B. Muss, G.S. Tell, L.D. Case, P. Robertson and B.M. Atwell, Perceptions of follow-up care in women with breast cancer, Am J Clin Oncol 14 (1991), 55-59.
11. P. Valagussa, J.D. Tess, A. Rossi, G. Tancini, A. Banfi and G. Bonadonna, Adjuvant CNIF effect on site of first recurrence, and appropriate follow- up intervals, in operable breast cancer with positive axillary nodes, Breast Cancer Res Treat 1 (1981), 349-356.
12. E.F. Scanlon, M.A. Oviedo, M.P. Cunningham, J.A. Caprim, J.D. Khandekar, E. Cohen et al., Preoperative and follow-up procedures on patients with breast cancer, Cancer 46 (1980), 977-979.
13. R. Qazi, J.L. Chuang and W. Drobyski, Estrogen receptors and the pattern of relapse in breast cancer, Arch Intern Med 144 (1984), 2365-2567.
14. F.C. Campbell, R.W. Blamey, C.W. Elston, R.I. Nicholson, K. Griffiths and J.L. Haybittle, Oestrogen-receptor status and sites of metastasis in breast cancer, Br J Cancer 44 (1981), 456-459.
15. M. Harris, A. Howell, M. Chrissohou, R.I. Swindell, M. Hudson and R.A. Sellwood, A comparison of the metastatic Pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast, Br J Cancer 50 (1984), 23-30.
16. J. Lamovec and A. Zidar, Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study, Arch Pathol Lab Med 115 (1991), 507-510.
17. A. Ahr, U. Holtrich, C. Solbach, A. Schad, K. Strebhardt, T. Kam et al., Molecular classification of breast cancer patients by gene expression profiling, J Pathol 195 (2001), 312-320.
18. A. Ahr, T. Karn, C. Solbach, T. Seiter, K. Strebhardt, U. Holtrich et al., Identification ofhigh riskbreast-cancer patients by gene expression profiling,Lancet 359 (2002), 131-132.
19. L.J. van't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao et al., Gene expression profiling predicts clinical outcome of breast cancer, Nature 415 (2002), 530-536.
20. M.J. van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, D.W. Voskuil et al., A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med 347 (2002), 1999-2009.
21. E. Hannisdal, S. Gundersen, S. Kvaloy, M.W. Lindegaard, M. Aas, A.M. Finnanger et al., Follow-up of breast cancer patients stage 1-11: A baseline strategy, Eur J Cancer 7 (1993), 992-997.
22. A.F. Jacobson, E.B. Cronin, P.C. Stomper and W.D. Kaplan, Bone scans with one or two new abnormalities in cancer patients with no known metastases: Frequency and serial scintigraphic behavior of benign and malignant lesions, Radiology 175 (1990), 229-232.
23. R.L. Wahl, R.L. Cody, G.D. Hutchins, E.E. Mudgett, Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy- D-glucose, Radiology 179 (1991), 765-770.
24. R.L. Wahl, R. Cody, G. Hutchins and E. Mudgett, Positronemission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro- D-glucose, N Engl J Med 324 (1991), 200.
25. R.W. Carlson, Biomarkers in the Surveillance of Early Breast Cancer, Seminars in Breast Disease (1999), 2.
26. M. Gion, R. Mione, A.E. Leon and R. Dittadi, Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer, Clin Chem 45 (1999), 630-637.
27. D.W. Chan, R.A. Beveridge, H. Muss, H.A. Fritsche, G. Hortobagyi, R. Theriault et al., Use of Truquant BR radiormmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease, J Clin Oncol 15 (1997), 2322-2328.
28. C.S. Liu, Y.Y. Shen, C.C. Lin, R.F. Yen and C.H. Kao, Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptornatically elevated tumor marker serum levels: A preliminary report, Jpn J Clin Oncol 32 (2002), 244-247.
29. W. Jager, The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements, Eur J Cancer Prev 2(Suppl 3) (1993), 133-139.
30. R.C. Bast, Jr., P. Ravdin, D.F. Hayes, S. Bates, H. Fritsche, Jr., J.M. Jessup et al., 2000 update of recommendations for the use oftumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology, J Clin Oncol 19 (2001), 1865-1878.
31. E. Grunfeld, D. Mant, P. Yudkin, R. Adewuyi-Dalton, D. Cole, J. Stewart et al., Routine follow up of breast cancer in primary care: Randomi sed trial, BMJ 313 (1996), 665-669.
32. J. Maher, J. Bradburn and R. Adewuyi-Dalton, Follow up in breast cancer. Patients prefer specialist follow up, Bmj 311 (1995),54.
33. M.S. Simon, M. Stano, M. Hussein, M. Hoff and D. Smith, An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer, Breast Cancer Res Treat 37 (1996), 39-47.
34. T.J. Smith, N.E. Davidson, D.V Schapira, E. Grunfeld, H.B. Muss, V.G. Vogel 3rd, et al., American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines, J Clin Oncol 17 (1999), 1080-1082.
35. R.W. Carlson, B.O. Anderson, W. Bensinger, C.E. Cox, N.E. Davidson, S.B. Edge et al., NCCN Practice Guidelines for Breast Cancer, Oncology (Huntingt) 14 (2000), 33-49.
36. M. Hugi, 1. Olivotto, A. Lees et al., Follow-up after treatment of breast cancer, Can Med Assoc J 158(Suppl 3S70) (1998).
37. N.B.C.C. Australia, National Breast Cancer Center, Clinical Practice Guidelines for the Management of Early Breast Cancer Follow-up. http://nbcc.org/ati/pages/info/resource/nbccpubs/clinprof/followup.htm. Accessed Dec. 2002.
38. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer Ann Oncol 12 (2001), 1047-1048.